Acid-suppressive therapy among infants and risk of anemia at 12 months of age

Objectives: Numerous studies have shown that links exist between exposure to acid suppression among adults and nutritional deficiencies, especially vitamin B12 and iron. While the use of acid suppression among children and infants is common, nutritional deficiency remains a concern but does not have...

Full description

Bibliographic Details
Main Authors: Ahmad Abu-Sulb, Rawan Al-Najjar, Rama Maghnam, Ashraf Ashhab
Format: Article
Language:English
Published: SAGE Publishing 2022-09-01
Series:SAGE Open Medicine
Online Access:https://doi.org/10.1177/20503121221123117
_version_ 1798003401123954688
author Ahmad Abu-Sulb
Rawan Al-Najjar
Rama Maghnam
Ashraf Ashhab
author_facet Ahmad Abu-Sulb
Rawan Al-Najjar
Rama Maghnam
Ashraf Ashhab
author_sort Ahmad Abu-Sulb
collection DOAJ
description Objectives: Numerous studies have shown that links exist between exposure to acid suppression among adults and nutritional deficiencies, especially vitamin B12 and iron. While the use of acid suppression among children and infants is common, nutritional deficiency remains a concern but does not have numerous studies to support it. We conducted a cohort study to examine this concern; the hypothesis we proposed is that acid-suppressive therapy (AST) during infancy is linked to anemia in the first year of life. Methods: This retrospective cohort study included infants born between 2017 and 2018 who visited Legacy Community Health. The inclusion criteria were exposure to acid suppression for a minimum of 1 month and a hemoglobin reading at 12–15 months. Infants who had hemoglobinopathies, failure to thrive, or malabsorption syndromes were excluded. Mean hemoglobin was calculated, and student’s t -test was applied to find statistical differences between the two groups. Change in weight before and after treatment was recorded. Occurrence of respiratory and gastroenterological adverse events was recorded in the exposed group. Results: Overall, 135 exposed infants were identified 135 controls were selected. The majority of the sample included Hispanic girls. Ranitidine was the most commonly prescribed medicine. The duration of treatment was 3 months. Weight improved significantly at termination of the treatment. There was no significant difference between the hemoglobin level of cases and controls, and both were not considered anemic. Conclusion: AST was not linked to anemia, despite the slightly lower hemoglobin in some cases. There were few weaknesses in our study; therefore, further studies can examine this link by focusing further on medication type and close follow-up. We found that although proton pump inhibitors are considered the first line of treatment, histamine-2 receptor antagonists were more frequently prescribed. Strategies to familiarize general pediatricians with the NSAPGHAN guidelines might be needed.
first_indexed 2024-04-11T12:06:59Z
format Article
id doaj.art-11dd726cefe9489582aa86b32ed267ea
institution Directory Open Access Journal
issn 2050-3121
language English
last_indexed 2024-04-11T12:06:59Z
publishDate 2022-09-01
publisher SAGE Publishing
record_format Article
series SAGE Open Medicine
spelling doaj.art-11dd726cefe9489582aa86b32ed267ea2022-12-22T04:24:42ZengSAGE PublishingSAGE Open Medicine2050-31212022-09-011010.1177/20503121221123117Acid-suppressive therapy among infants and risk of anemia at 12 months of ageAhmad Abu-Sulb0Rawan Al-Najjar1Rama Maghnam2Ashraf Ashhab3Division of Pediatrics, Legacy Community Health, Houston, TX, USADivision of Neonatology, Baylor College of Medicine, Houston, TX, USADepartment of Pediatrics, Monmouth Medical Center, Long Branch, NJ, USADivision of Digestive & Liver Diseases, Cedars-Sinai Medical Center, Los Angeles, CA, USAObjectives: Numerous studies have shown that links exist between exposure to acid suppression among adults and nutritional deficiencies, especially vitamin B12 and iron. While the use of acid suppression among children and infants is common, nutritional deficiency remains a concern but does not have numerous studies to support it. We conducted a cohort study to examine this concern; the hypothesis we proposed is that acid-suppressive therapy (AST) during infancy is linked to anemia in the first year of life. Methods: This retrospective cohort study included infants born between 2017 and 2018 who visited Legacy Community Health. The inclusion criteria were exposure to acid suppression for a minimum of 1 month and a hemoglobin reading at 12–15 months. Infants who had hemoglobinopathies, failure to thrive, or malabsorption syndromes were excluded. Mean hemoglobin was calculated, and student’s t -test was applied to find statistical differences between the two groups. Change in weight before and after treatment was recorded. Occurrence of respiratory and gastroenterological adverse events was recorded in the exposed group. Results: Overall, 135 exposed infants were identified 135 controls were selected. The majority of the sample included Hispanic girls. Ranitidine was the most commonly prescribed medicine. The duration of treatment was 3 months. Weight improved significantly at termination of the treatment. There was no significant difference between the hemoglobin level of cases and controls, and both were not considered anemic. Conclusion: AST was not linked to anemia, despite the slightly lower hemoglobin in some cases. There were few weaknesses in our study; therefore, further studies can examine this link by focusing further on medication type and close follow-up. We found that although proton pump inhibitors are considered the first line of treatment, histamine-2 receptor antagonists were more frequently prescribed. Strategies to familiarize general pediatricians with the NSAPGHAN guidelines might be needed.https://doi.org/10.1177/20503121221123117
spellingShingle Ahmad Abu-Sulb
Rawan Al-Najjar
Rama Maghnam
Ashraf Ashhab
Acid-suppressive therapy among infants and risk of anemia at 12 months of age
SAGE Open Medicine
title Acid-suppressive therapy among infants and risk of anemia at 12 months of age
title_full Acid-suppressive therapy among infants and risk of anemia at 12 months of age
title_fullStr Acid-suppressive therapy among infants and risk of anemia at 12 months of age
title_full_unstemmed Acid-suppressive therapy among infants and risk of anemia at 12 months of age
title_short Acid-suppressive therapy among infants and risk of anemia at 12 months of age
title_sort acid suppressive therapy among infants and risk of anemia at 12 months of age
url https://doi.org/10.1177/20503121221123117
work_keys_str_mv AT ahmadabusulb acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage
AT rawanalnajjar acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage
AT ramamaghnam acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage
AT ashrafashhab acidsuppressivetherapyamonginfantsandriskofanemiaat12monthsofage